• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cytek Biosciences, Inc. - Common Stock (NQ:CTKB)

    5.870 +0.060 (+1.03%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,099,466
    Open 5.860
    Bid (Size) 5.740 (400)
    Ask (Size) 5.950 (3,000)
    Prev. Close 5.810
    Today's Range 5.750 - 5.940
    52wk Range 3.310 - 6.180
    Shares Outstanding 136,360,208
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
    Industry’s First End-to-End Flow Cytometry Platform Covering Panel Design Through Data Analysis 
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill

    Performance

    52-Week Range 5.0% below 52-week high
    5.870
    3.3152W Low 6.1852W High
    1 Week 1.9% below 1-week high
    5.531W Low 5.991W High

    Cytek Biosciences, Inc. - Common Stock (CTKB) traded between $3.31 and $6.18 over the past 52 weeks and last traded at $5.87, 5.0% below its 52-week high. Over the past week it ranged between $5.53 and $5.99.

    Past 12 Months
    +2.3%
    +25.2%
    +27.1%
    +29.9%
    +19.3%
    +60.8%
    1W +$0.13
    1M +$1.18
    3M +$1.25
    6M +$1.35
    YTD +$0.95
    1Y +$2.22

    CTKB was +60.8% over the past year, +29.9% over six months, +19.3% year to date, +2.3% in the last week.

    12 Months vs Market
    CTKB
    +60.8%
    DIA
    +9.9%
    SPY
    +15.0%
    QQQ
    +23.7%
    IWM
    +15.4%

    Over the past 12 months CTKB returned +60.8% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

    Volume & Liquidity 1.10× 3-mo avg
    Today 1,099,466 3-mo avg 998.0K
    1W
    1.2M
    1M
    1.4M
    3M
    998.0K
    6M
    1.2M
    YTD
    1.0M
    1Y
    1.1M

    CTKB most recently traded 1,099,466 shares against a 3-month average daily volume of 998.0K.

    More News

    Read More
    News headline image
    Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
    From Cytek Biosciences, Inc.; Sysmex Europe SE
    Via GlobeNewswire
    Cytek Biosciences Inc (NASDAQ:CTKB) Reports Q4 2025 Revenue Beat and Mixed Earnings ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 5, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 6, 2025 ↗
    Via Benzinga
    News headline image
    Beyond The Numbers: 4 Analysts Discuss Cytek Biosciences Stock ↗
    Via Benzinga
    News headline image
    Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek (CTKB) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Intellectual Property World Trade
    News headline image
    Cytek Biosciences Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
    From USA News Group
    Via GlobeNewswire
    News headline image
    Cytek (CTKB) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek (CTKB) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Intellectual Property World Trade
    News headline image
    Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗
    Via Benzinga
    News headline image
    TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek (CTKB) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Intellectual Property World Trade
    News headline image
    Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA
    From Cytek Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
    From Cytek Biosciences, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Cytek Biosciences, Inc. - Common Stock publicly traded?
    Yes, Cytek Biosciences, Inc. - Common Stock is publicly traded.
    What exchange does Cytek Biosciences, Inc. - Common Stock trade on?
    Cytek Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cytek Biosciences, Inc. - Common Stock?
    The ticker symbol for Cytek Biosciences, Inc. - Common Stock is CTKB on the Nasdaq Stock Market
    What is the current price of Cytek Biosciences, Inc. - Common Stock?
    The current price of Cytek Biosciences, Inc. - Common Stock is 5.870
    When was Cytek Biosciences, Inc. - Common Stock last traded?
    The last trade of Cytek Biosciences, Inc. - Common Stock was at 10/02/26 04:00 PM ET
    What is the market capitalization of Cytek Biosciences, Inc. - Common Stock?
    The market capitalization of Cytek Biosciences, Inc. - Common Stock is 800.43M
    How many shares of Cytek Biosciences, Inc. - Common Stock are outstanding?
    Cytek Biosciences, Inc. - Common Stock has 800M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.